Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
(2024) In British Journal of Cancer 131(2). p.299-304- Abstract
Background: Patients with ruptured gastrointestinal stromal tumour (GIST) have poor prognosis. Little information is available about how adjuvant imatinib influences survival. Methods: We explored recurrence-free survival (RFS) and overall survival (OS) of patients with ruptured GIST who participated in a randomised trial (SSG XVIII/AIO), where 400 patients with high-risk GIST were allocated to adjuvant imatinib for either 1 year or 3 years after surgery. Of the 358 patients with confirmed localised GIST, 73 (20%) had rupture reported. The ruptures were classified retrospectively using the Oslo criteria. Results: Most ruptures were major, four reported ruptures were reclassified unruptured. The 69 patients with rupture had inferior RFS... (More)
Background: Patients with ruptured gastrointestinal stromal tumour (GIST) have poor prognosis. Little information is available about how adjuvant imatinib influences survival. Methods: We explored recurrence-free survival (RFS) and overall survival (OS) of patients with ruptured GIST who participated in a randomised trial (SSG XVIII/AIO), where 400 patients with high-risk GIST were allocated to adjuvant imatinib for either 1 year or 3 years after surgery. Of the 358 patients with confirmed localised GIST, 73 (20%) had rupture reported. The ruptures were classified retrospectively using the Oslo criteria. Results: Most ruptures were major, four reported ruptures were reclassified unruptured. The 69 patients with rupture had inferior RFS and OS compared with 289 patients with unruptured GIST (10-year RFS 21% vs. 55%, OS 59% vs. 78%, respectively). Three-year adjuvant imatinib did not significantly improve RFS or OS of the patients with rupture compared with 1-year treatment, but in the largest mutational subset with KIT exon 11 deletion/indel mutation OS was higher in the 3-year group than in the 1-year group (10-year OS 94% vs. 54%). Conclusions: About one-fifth of ruptured GISTs treated with adjuvant imatinib did not recur during the first decade of follow-up. Relatively high OS rates were achieved despite rupture. Clinical Trial Registration: NCT00116935.
(Less)
- author
- organization
- publishing date
- 2024-07-22
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Cancer
- volume
- 131
- issue
- 2
- pages
- 6 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:38862742
- scopus:85195671439
- ISSN
- 0007-0920
- DOI
- 10.1038/s41416-024-02738-z
- language
- English
- LU publication?
- yes
- id
- 1a9c6a8e-dbbd-4da1-90c9-93db38c37a3b
- date added to LUP
- 2024-09-16 08:56:49
- date last changed
- 2024-09-17 03:00:12
@article{1a9c6a8e-dbbd-4da1-90c9-93db38c37a3b, abstract = {{<p>Background: Patients with ruptured gastrointestinal stromal tumour (GIST) have poor prognosis. Little information is available about how adjuvant imatinib influences survival. Methods: We explored recurrence-free survival (RFS) and overall survival (OS) of patients with ruptured GIST who participated in a randomised trial (SSG XVIII/AIO), where 400 patients with high-risk GIST were allocated to adjuvant imatinib for either 1 year or 3 years after surgery. Of the 358 patients with confirmed localised GIST, 73 (20%) had rupture reported. The ruptures were classified retrospectively using the Oslo criteria. Results: Most ruptures were major, four reported ruptures were reclassified unruptured. The 69 patients with rupture had inferior RFS and OS compared with 289 patients with unruptured GIST (10-year RFS 21% vs. 55%, OS 59% vs. 78%, respectively). Three-year adjuvant imatinib did not significantly improve RFS or OS of the patients with rupture compared with 1-year treatment, but in the largest mutational subset with KIT exon 11 deletion/indel mutation OS was higher in the 3-year group than in the 1-year group (10-year OS 94% vs. 54%). Conclusions: About one-fifth of ruptured GISTs treated with adjuvant imatinib did not recur during the first decade of follow-up. Relatively high OS rates were achieved despite rupture. Clinical Trial Registration: NCT00116935.</p>}}, author = {{Joensuu, Heikki and Reichardt, Annette and Eriksson, Mikael and Hohenberger, Peter and Boye, Kjetil and Cameron, Silke and Lindner, Lars H. and Jost, Philipp J. and Bauer, Sebastian and Schütte, Jochen and Lindskog, Stefan and Kallio, Raija and Jaakkola, Panu M. and Goplen, Dorota and Wardelmann, Eva and Reichardt, Peter}}, issn = {{0007-0920}}, language = {{eng}}, month = {{07}}, number = {{2}}, pages = {{299--304}}, publisher = {{Nature Publishing Group}}, series = {{British Journal of Cancer}}, title = {{Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial}}, url = {{http://dx.doi.org/10.1038/s41416-024-02738-z}}, doi = {{10.1038/s41416-024-02738-z}}, volume = {{131}}, year = {{2024}}, }